Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab.
García-Cadenas I, Castillo N, Martino R, Barba P, Esquirol A, Novelli S, Orti G, Garrido A, Saavedra S, Moreno C, Granell M, Briones J, Brunet S, Navarro F, Ruiz I, Rabella N, Valcárcel D, Sierra J. García-Cadenas I, et al. Among authors: orti g. Bone Marrow Transplant. 2015 Apr;50(4):579-84. doi: 10.1038/bmt.2014.298. Epub 2015 Jan 12. Bone Marrow Transplant. 2015. PMID: 25581404
Validation of a new integrated prognostic score to predict non-relapse mortality in patients undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation.
Barba P, Martino R, Orti G, Esquirol A, Perez-Hoyos S, Sierra J, Valcárcel D. Barba P, et al. Among authors: orti g. Bone Marrow Transplant. 2015 Oct;50(10):1371-4. doi: 10.1038/bmt.2015.144. Epub 2015 Jun 22. Bone Marrow Transplant. 2015. PMID: 26098954 No abstract available.
Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
Orti G, Sanz J, Bermudez A, Caballero D, Martinez C, Sierra J, Cabrera Marin JR, Espigado I, Solano C, Ferrà C, García-Noblejas A, Jimenez S, Sampol A, Yañez L, García-Gutiérrez V, Pascual MJ, Jurado M, Moraleda JM, Valcarcel D, Sanz MA, Carreras E, Duarte RF. Orti G, et al. Biol Blood Marrow Transplant. 2016 Mar;22(3):584-8. doi: 10.1016/j.bbmt.2015.11.012. Epub 2015 Nov 26. Biol Blood Marrow Transplant. 2016. PMID: 26631751 Free article. Clinical Trial.
Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.
Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA. Kharfan-Dabaja MA, et al. Among authors: orti g. Bone Marrow Transplant. 2017 Mar;52(3):438-444. doi: 10.1038/bmt.2016.269. Epub 2016 Nov 7. Bone Marrow Transplant. 2017. PMID: 27819684 Free article.
Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
Ortí G, Sanz J, García-Cadenas I, Sánchez-Ortega I, Alonso L, Jiménez MJ, Sisinni L, Azqueta C, Salamero O, Badell I, Ferra C, de Heredia CD, Parody R, Sanz MA, Sierra J, Piñana JL, Querol S, Valcárcel D. Ortí G, et al. Exp Hematol. 2018 Jun;62:24-32. doi: 10.1016/j.exphem.2018.03.002. Epub 2018 Mar 8. Exp Hematol. 2018. PMID: 29526774 Free article.
144 results